Publication | Open Access

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

Lymphoid NeoplasiaOncologyImmune Checkpoint InhibitorBiosimilar Ct-p10Low-tumour-burden Follicular LymphomaCancer TreatmentImmunotherapyMedicineRadiation OncologyRadiologyHealth Sciences